Congressional Funding Status
The Department of Health and Human Services (HHS), including NIH, is operating under a Continuing Resolution (Public Law 117-180) signed by President Biden on September 30, 2022. This CR continues government operations through December 16, 2022 at Fiscal Year (FY) 2022 enacted levels. During a CR, the Institute sets interim funding policies to ensure that it can meet funding commitments made in prior years. These policies may be revisited at such time that the Agency receives a full year budget.
In certain cases NINDS applies permanent or temporary budget reductions to awards. See below for details on when these occur.
Competing Award Administrative Reductions and Funding Policies
- Non-Modular R01s will receive a 17.5% administrative cut; modular R01s and most other funding mechanisms are generally awarded with no administrative reduction to the IRG-approved funding level.
- Salaries, stipends, and Training Funds are limited to the levels published by the NIH. We will reduce budgets when these caps are exceeded. For additional information, see our salary cap, stipends, and training funds page.
- No inflationary increases are provided in calculating future year commitments. For more details about this and related funding policies, see our Funding Policies page.
Noncompeting Award Adjustment and Funding Policies
-
During the current Continuing Resolution period, NINDS will generally fund noncompeting continuation awards (Type 5) at 90% of the level indicated on the previous Notice of Award. After appropriations are enacted, we intend to adjust awards levels to 100% of the previously committed level. As an upward adjustment is dependent on final budget levels this is not guaranteed, and institutions are expected to monitor their expenditures carefully during this period.
Understanding Your Funding Likelihood
The tables below provide guidelines to applicants trying to assess their likelihood of funding. There are a few important points of note that applicants must keep in mind when reviewing this information:
Key Points
- Funding isn’t official until a Notice of Award (NoA) is issued.
- NINDS Program Staff are not able to say anything more definitive until after the NINDS Advisory Council meets and the NoA has been released.
- You can find more details on how to assess funding likelihood and when that determination is likely to be made by visiting the NINDS Post Review: Next Steps page.
Applications with a Percentile Score
This table applies to applications receiving a percentiled score. While a score within the paylines shown in the table below suggests a high likelihood of funding, it is not a guarantee; there are rare circumstances where an application within the payline is not funded.
|
Applicant has >$2M in NIH Funding^ |
Standard |
Early Stage Investigator (ESI) |
AD/ADRD* |
AD/ADRD* ESI |
---|---|---|---|---|---|
R03 |
7% |
14% |
N/A |
25% |
N/A |
R15 |
7% |
14% |
N/A |
25% |
N/A |
R21 |
7% |
14% |
N/A |
25% |
N/A |
R01 |
7% |
14% |
25% |
25% |
30% |
^ Applications with greater than $2 million in NIH funding are subject to Special Council Review.
*For AD/ADRD applications, NINDS follows the same payline as NIA. Please see the NIA Funding Line Policy for more information.
Non-percentiled applications
This table applies to applications receiving only a priority score. There are no paylines for non-percentiled applications; rather, applications are individually considered and assessed for portfolio balance based on funds available. The table below is intended to give investigators an indication of their likelihood of funding based on recent trends. It is not intended to suggest that funding at a particular score is guaranteed.
SBIR/STTR
Most applications funded (>75%) | Some applications funded | Few applications funded | |
---|---|---|---|
R41 | ≤ 25 | 26 - 35 | > 35 |
R42 | ≤ 25 | 26 - 30 | > 30 |
R43 | ≤ 25 | 26 - 30 | > 30 |
R44 | ≤ 22 | 23 - 30 | > 30 |
SB1 | ≤ 22 | 23 - 30 | > 30 |
U44 | ≤ 25 | 26 - 30 | > 30 |
Fellowships, Training, Career Development, Research Education
Most applications funded (>75%) | Some applications funded | Few applications funded | |
---|---|---|---|
F30 | ≤ 30 | 31 - 35 | > 35 |
F31 | ≤ 20 | 21 - 26 | > 26 |
F32 | ≤ 30 | 31 - 37 | > 37 |
F99 | ≤ 35 | 36 - 40 | > 40 |
K01 | ≤ 30 | 31 - 45 | > 45 |
K08 | ≤ 30 | 31 - 40 | > 40 |
K23 | ≤ 30 | 31 - 37 | > 37 |
K99 | ≤ 30 | 31 - 37 | > 37 |
R25 | ≤ 30 | 31 - 40 | > 40 |
T32 | ≤ 30 | 31 - 35 | > 35 |
Other Research Grants
Most applications funded (>75%) | Some applications funded | Few applications funded | |
---|---|---|---|
P01 | ≤ 25 | 26 - 30 | > 30 |
P50 | ≤ 25 | 26 - 30 | > 30 |
R34 | ≤ 30 | 31 - 40 | > 40 |
R35 | ≤ 25 | 26 - 30 | > 30 |
R61/R33 | ≤ 25 | 26 - 30 | > 30 |
U01 | ≤ 25 | 26 - 30 | > 30 |
U19 | ≤ 30 | 31 - 40 | > 40 |
U54 | ≤ 25 | 26 - 30 | > 30 |
UG3/UH3 | ≤ 30 | 31 - 35 | > 35 |
Historical NINDS Paylines and Funding Policies
For historical paylines and funding policies, please see below: